Latest market price
19.57
-0.31-1.56%
OverviewShort InterestFilings
KVUEQT58Kenvue Inc.·NYSE
19.57-1.56%
News
Down 1.6% — Kimberly-Clark: The Dividend Survives Kenvue, But Expect Token Raises (seekingalpha.com).
Medium confidence
TA
Loading chart...
Screen all →
KMB-1.93%$110.15EL+0.88%$108.67CHD-3.37%$105.19CL-3.44%$94.04CLX-2.55%$86.40UL-1.15%$66.23ELF-0.65%$114.24REYN-2.50%$23.02
Snapshot
IndexS&P 500P/E22.49EPS (ttm)0.87Insider Own1.66%Shs Outstand1.92BPerf Week3.49%
Market Cap37.59BForward P/E15.71EPS next Y1.25Insider Trans-0.13%Shs Float1.92BPerf Month11.13%
Enterprise Value44.96BPEG4.53EPS next Q-Inst Own-Short Float3.01%Perf Quarter0.46%
Income1.66BP/S2.44EPS this Y14.03%Inst Trans-Short Ratio2.62Perf Half Y11.89%
Sales15.41BP/B3.56EPS next Y5.98%ROA6.20%Short Interest57.66MPerf YTD13.45%
Book/sh5.49P/C33.86EPS next 5Y4.97%ROE15.58%52W High20.13 -2.78%Perf Year28.83%
Cash/sh0.58P/FCF17.76EPS past 3/5Y-11.05% -ROIC10.07%52W Low14.02 39.59%Perf 3Y-2.44%
Dividend Est.0.84 (4.29%)EV/EBITDA14.20Sales past 3/5Y0.39% 0.89%Gross Margin58.19%Volatility2.12% 1.72%Perf 5Y-
Dividend TTM1.04 (5.33%)EV/Sales2.92EPS Y/Y TTM61.11%Oper. Margin19.52%ATR (14)0.38Perf 10Y-
Dividend Ex-DateSep 21, 2026Quick Ratio0.71Sales Y/Y TTM-0.30%Profit Margin10.76%RSI (14)67.44Recom2.71
Dividend Gr. 3/5Y-Current Ratio1.01EPS Q/Q6.90%SMA207.64%Beta0.06Target Price19.50
Payout0.66%Debt/Eq0.79Sales Q/Q3.02%SMA506.59%Rel Volume0.49Prev Close19.88
Employees21,890LT Debt/Eq0.66EarningsOct 30SMA2007.94%Avg Volume22.60MPrice19.57
IPO DateMay 04, 2023Option/ShortYes / YesEPS/Sales Surpr.-2.73% -0.27%Net Debt/EBITDA2.33Volume11,066,955Change-1.56%
Analyst Ratings
DateActionAnalystRatingTarget
Jul-21-26ReiteratedBarclaysEqual Weight$18 → $19
Jul-16-26ReiteratedUBSNeutral$19 → $20
Apr-14-26ReiteratedBarclaysEqual Weight$17 → $18
Feb-18-26ReiteratedUBSNeutral$17 → $19
Feb-18-26ReiteratedCanaccord GenuityHold$15 → $18
Jan-30-26DowngradeJefferiesBuy → Hold$23 → $18
Oct-29-25DowngradeCanaccord GenuityBuy → Hold$29 → $15
Oct-28-25ReiteratedEvercore ISIIn Line$18
Oct-27-25ReiteratedJefferiesBuy$27 → $23
Oct-24-25ReiteratedDeutsche BankHold$20 → $18
Latest News· Times ET
Oct-23-26
Oct-23-2611:28AM
Kimberly-Clark: The Dividend Survives Kenvue, But Expect Token Raisesseekingalpha.com
11:19AM
Is Kenvue (KVUE) Below Fair Value After Its 40% Run?Yahoo
Oct-22-26
Oct-22-2611:16AM
3 Beauty Stocks to Explore as Consumer Preferences Reshape the Marketzacks.com
Oct-21-26
Oct-21-2605:00PM
Kenvue to Announce Third Quarter 2026 Results on October 30, 2026businesswire.com
Oct-19-26
Oct-19-2603:32PM
October's 5 Dividend Growth Stocks With Yields Up To 7.99%seekingalpha.com
Oct-17-26
Oct-17-2603:37AM
First Citizens Bank & Trust Co. Purchases New Position in Kenvue Inc. $KVUEdefenseworld.net
Oct-15-26
Oct-15-2605:17PM
Kimberly Clark (KMB) Stock Trades At A Discount As Shares Fell 13%Yahoo
Oct-13-26
Oct-13-2610:43AM
Kimberly-Clark, Kenvue Win Conditional EU Approval for $40 Billion Tie-Upwsj.com
07:00AM
Kimberly-Clark Announces Successful Consent Solicitations for Kenvue Notes and Amendment to Terms of Exchange Offersprnewswire.com
Oct-08-26
Oct-08-2607:45AM
Market Concentration Is Spooking Wall Street—I'm Buying Kenvue247wallst.com
Oct-06-26
Oct-06-2610:40AM
NWL or KVUE: Which Is the Better Value Stock Right Now?Yahoo
Oct-04-26
Oct-04-2610:15AM
4 Dividend Aristocrats Still Raising Their Payouts No Matter What Their Stock Price Did247wallst.com
Oct-01-26
Oct-01-2607:00AM
Kimberly-Clark Announces Planned Executive Transitions and Updates to Post-Closing Leadership Teamprnewswire.com
Sep-30-26
Sep-30-2602:45PM
Kimberly-Clark Keeps Raising Its Dividend. The Question Is Whether It Is Keeping Up With Your CostsYahoo
08:50AM
5 ‘Bulletproof’ Dividend Kings Boomers Should Buy Now Before the Market Shifts247wallst.com
Company

Kenvue Inc. functions as a global leader in the consumer health sector. The company structures its operations across three primary divisions: Self Care, Skin Health and Beauty, and Essential Health. Within the Self Care unit, it offers a diverse range of products for common conditions like coughs, colds, and allergies, in addition to pain relief, digestive health, and smoking cessation aids, featuring prominent brands such as Tylenol, Nicorette, and Zyrtec. The Skin Health and Beauty segment delivers various solutions for facial, body, hair, and sun protection, recognized under popular labels including Neutrogena, Aveeno, and OGX. Moreover, the Essential Health category provides oral hygiene, infant care, feminine wellness, and wound treatment products, marketed through esteemed brands like Listerine, Johnson's, Band-Aid, and Stayfree. Established in 2022, Kenvue Inc. maintains its corporate headquarters in Skillman, New Jersey, and operates as a subsidiary of Johnson & Johnson.

Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements
DataTimeframe
Line Item (USD, M)
TTM
—
FY 2025
12/28/2025
FY 2024
12/29/2024
FY 2023
12/31/2023
FY 2022
12/31/2022
FY 2021
12/31/2021
FY 2020
12/31/2020
FY 2019
12/31/2019
Total Revenue15,40815,12415,455—————
Cost of Goods Sold Incl. D&A6,4426,3326,496—————
Gross Profit8,9668,7928,959—————
Selling, General and Administrative Excl. Other4,5006,0886,027—————
Research and Development843820—————
Other Operating Expense1,380-3821,091—————
Operating Income3,0082,7041,841—————
Interest Expense376379431—————
Unusual Expense
————————
Non-Operating Income (Expense)-409-3265—————
Net Income Before Taxes2,2231,9991,415—————
Income Taxes565529385—————
Consolidated Net Income1,6581,4701,030—————
Net Income From Continuing Operations1,6581,4701,030—————
Net Income1,6581,4701,030—————
EPS (Recurring)0.870.770.54—————
EPS (Basic, Before Extraordinaries)0.870.770.54—————
EPS (Diluted)0.870.760.54—————
EBITDA3,1662,9352,468—————
Other After Tax Adjustments
————————
Stock Option Compensation Expense
————————
Price To Earnings Ratio22.4922.6239.87—————
Price To Sales Ratio2.442.182.67—————
Gross Margin58.1958.1357.97—————
Operating Margin19.5217.8811.91—————
Net Margin10.769.726.66—————
Shares Outstanding1,9201,9171,915—————
Market Capitalization37,57432,95341,230—————
Operating Lease Expense
————————
Unlock full historical data
See years of past statements with Premium.
Unlock with Premium
Insider Trading Volume
$22.76$20.31$17.87$15.43$12.98● Close Price0.00M27.75M55.49M83.24M110.99MUSD Trades VolumeOctNovDec2026FebMarAprMayJunJulAugSepOct
Insider Trading
InsiderRelationshipDateTransactionCost#SharesValue ($)#Shares TotalSEC Form 4
Wondrasch MichaelChief Tech & Data OfficerOct 01 '26Option Exercise0.0066,029066,029Oct 05
Stevens MeredithChief Operations OfficerSep 25 '26Option Exercise0.001,461094,653Sep 29
Dasgupta AnindyaGroup President APACJul 31 '26Option Exercise0.0016,419016,419Aug 04
Howlett HeatherCFO & CAOJun 10 '26Sale18.113,70066,98929,288Jun 12
Curado Gomes de Lemos LeonardoGroup President LATAMMay 01 '26Option Exercise0.0024,248024,248May 26
Orlando MatthewGeneral CounselMay 08 '26Sale17.6638,491679,6910May 12
Stevens MeredithChief Operations OfficerMar 10 '26Option Exercise0.005,169094,877Mar 12
Alvarado LuaniChief People OfficerMar 10 '26Option Exercise0.004,222062,797Mar 12
Lawson CarltonGroup President EMEA & LAMar 10 '26Option Exercise0.006,1580111,415Mar 12
Howlett HeatherVP & Chief Accounting OfficerMar 05 '26Option Exercise0.002,723033,921Mar 09
Lawson CarltonGroup President EMEA & LAMar 05 '26Option Exercise0.007,7360105,257Mar 09
Alvarado LuaniChief People OfficerMar 05 '26Option Exercise0.004,289061,365Mar 09
Stevens MeredithChief Operations OfficerMar 05 '26Option Exercise0.006,178092,224Mar 09
Howlett HeatherVP & Chief Accounting OfficerMar 03 '26Option Exercise0.001,534031,725Mar 04
Stevens MeredithChief Operations OfficerFeb 13 '26Option Exercise0.0028,040090,862Feb 18
open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR
QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.